Guo Ruijun, Xu Jiajun, Li Chunxia, Mo Chune, Ou Minglin
Laboratory Center, Guangxi Key Laboratory of Metabolic Reprogramming and Intelligent Medical Engineering for Chronic Diseases, The Second Affiliated Hospital of Guilin Medical University, Guilin, 541199, China.
Laboratory Center, Guangxi Health Commission Key Laboratory of Glucose and Lipid Metabolism Disorders, The Second Affiliated Hospital of Guilin Medical University, Guilin, 541199, China.
Discov Oncol. 2025 Aug 25;16(1):1623. doi: 10.1007/s12672-025-03416-z.
Tumor-derived exosomes testing can be effective in diagnosing disease and assisting in the treatment of disease. Our study utilizes bibliometric analysis to identify research hotspots related to tumor-derived exosomes, predict emerging research frontiers and development trends, and offer diverse perspectives for advancing research in this field.
Search the Web of Science Core Collection for English-language literature published on the field of tumor-derived exosomes from 2015 to 2024. CiteSpace(6.2.R3) software was utilized to visualize the distribution of countries/regions, institutions, authors, co-cited authors, and co-cited journals within the relevant literature. Additionally, co-occurrence, clustering, and emergence analyses were conducted on the co-cited references.
An analysis of 2523 articles meeting the inclusion criteria revealed a steady increase in the number of publications in this field over the past decade. In terms of countries/regions, institutions, authors, and journals that published articles, the most productive were China, Ministry of Education-China, Theresa L. Whiteside, and CANCER RES, respectively. The most influential were The United States, Harvard University, Theresa L. Whiteside, and CANCER RES, respectively. The mechanisms underlying exosomal PD-L1 and engineered exosomes are currently prominent research foci, warranting meticulous examination by the academic community.
Within the field of research on tumor-derived exosomes, current investigations appear largely concentrated on the exosome PD-L1 mechanism and engineered exosomes. Possible future research hotspots will focus on the use of engineered exosomes to target tumor cells and as a drug delivery platform for more precise therapeutic targeting.
肿瘤来源外泌体检测在疾病诊断和治疗辅助方面可能具有有效性。我们的研究利用文献计量分析来识别与肿瘤来源外泌体相关的研究热点，预测新兴的研究前沿和发展趋势，并为推进该领域的研究提供多样化的视角。
在科学网核心合集中搜索2015年至2024年发表的关于肿瘤来源外泌体领域的英文文献。使用CiteSpace（6.2.R3）软件来可视化相关文献中国家/地区、机构、作者、共被引作者和共被引期刊的分布情况。此外，对共被引参考文献进行共现、聚类和突现分析。
对2523篇符合纳入标准的文章进行分析发现，在过去十年中该领域的出版物数量稳步增加。在发表文章的国家/地区、机构、作者和期刊方面，产量最高的分别是中国、中国教育部、特里萨·L·怀特赛德和《癌症研究》。最具影响力的分别是美国、哈佛大学、特里萨·L·怀特赛德和《癌症研究》。外泌体PD-L1和工程化外泌体的潜在机制目前是突出的研究重点，值得学术界仔细研究。
在肿瘤来源外泌体的研究领域中，目前的研究似乎主要集中在外泌体PD-L1机制和工程化外泌体上。未来可能的研究热点将集中在利用工程化外泌体靶向肿瘤细胞以及作为更精确治疗靶向的药物递送平台。
